Microbial resistance associated with IPCSL in an adult ICU in Ceará

Authors

DOI:

https://doi.org/10.54620/cadesp.v20i1.2661

Keywords:

Drug Resistance Microbial, Sepsis, Health Surveillance, Intensive Care Units

Abstract

Objective: To describe the microbial resistance (MR) profile associated with laboratory-confirmed primary bloodstream infections (LCPBIs) reported in adult intensive care units (ICUs) in Ceará, from 2021 to 2023. Methods: A cross-sectional, descriptive, retrospective study with secondary data aggregated from the Brazilian Health Regulatory Agency (ANVISA), derived from notifications of healthcare-associated infections (HAIs) and MR; records with identified microorganisms and sensitivity testing were included. Results: The incidence density (ID) ranged from 3.45 to 10.51 per 1,000 patient-days. In Gram-negative bacteria, high resistance to cephalosporins (CEF) and carbapenems (CARB) was observed in Klebsiella pneumoniae, Acinetobacter spp., and Enterobacter spp., in addition to significant resistance to ceftazidime/avibactam (CAZ-AVI) in 2023. Among Gram-positive bacteria, resistance to vancomycin (VANCO) in enterococci and to oxacillin (OXA) in staphylococci stood out. Conclusions: The findings reinforce the surveillance of HAIs and the qualification of actions for prevention, control, and rational use of antimicrobials.  

Downloads

Download data is not yet available.

Author Biographies

  • Daniel Moreira Alves da Silva

    Farmacêutico formado pela Universidade Federal do Ceará (UFC), além de mestre e doutor pela mesma instituição. Possui especialização em Farmácia Clínica pela Universidade de Fortaleza (Unifor). Servidor Público Federal da carreira de Tecnologista do quadro permanente do Ministério da Saúde (MS), lotado na Secretaria de Vigilância em Saúde e Ambiente (SVSA/MS). Pesquisador colaborador do Laboratório de Neuropsicofarmacologia do Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), vinculado à UFC

  • Lucielmo Faustino Souza

    Farmacêutico formado pela Universidade Federal do Ceará. Especialista em Hematologia e Hemoterapia pela Universidade Estadual do Ceará e em Infectologia pela modalidade de Residência Multiprofissional da Escola de Saúde Pública do Ceará em parceria com o Hospital São José de Doenças Infecciosas. Mestre em Patologia pela Universidade Federal do Ceará e atualmente Doutorando em Patologia pela mesma instituição.

  • João Victor Souza Oliveira

    Farmacêutico e mestre em Farmacologia pela Universidade Federal do Ceará (UFC). Pós-graduado em Farmácia Clínica e Pres-crição Farmacêutica pela Universidade de Fortaleza (UNIFOR). Atualmente é douto-rando em Farmacologia pela UFC, atuando no laboratório de Neuropsicofarmacologia (LNF) do Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM)

References

1. World Health Organization. Global antibiotic resistance surveillance report 2025 [online]. Geneva: World Health Organization; 2025 [citado 2026 fev 01]. Disponível em: https://www.who.int/publications/i/item/97892401163372.

2. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet. 399(10325), 629-655. doi: 10.1016/S0140-6736(21)02724-0. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0

3. World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance [online]. Geneva: World Health Organization; 2024 [citado 2026 fev 01]. Disponível em: https://www.who.int/publications/i/item/97892400934614.

4. Interagency Coordination Group on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections: report to the Secretary-General of the United Nations [online]. Geneva: World Health Organization; 2019 [citado 2026 fev 01]. Disponível em: https://www.who.int/publications/i/item/no-time-to-wait-securing-the-future-from-drug-resistant-infections.

5. Organisation for Economic Co-operation and Development (OECD). Stemming the superbug tide: just a few dollars more [online]. Paris: OECD Publishing; 2018 [citado 2026 fev 01]. Disponível em: https://www.oecd.org/en/publications/stemming-the-superbug-tide_9789264307599-en.html.

6. Agência Nacional de Vigilância Sanitária (BR). Programa Nacional de Prevenção e Controle de Infecções Relacionadas à Assistência à Saúde (PNPCIRAS) 2021–2025 [online]. Brasília (DF): Agência Nacional de Vigilância Sanitária; 2021 [citado 2026 fev 01]. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/servicosdesaude/prevencao-e-controle-de-infeccao-e-resistencia-microbiana/pnpciras-e-pan-servicos-de-saude.

7. Secretaria da Saúde do Estado do Ceará. Coordenadoria de Vigilância Sanitária. Plano Estadual para Prevenção e Controle de Infecções Relacionadas à Assistência à Saúde nos Serviços de Saúde do Estado do Ceará 2024–2027 [online]. Fortaleza (CE): Secretaria da Saúde do Estado do Ceará; 2024 [citado 2026 fev 01]. Disponível em: http://www.saude.ce.gov.br/wp-content/uploads/sites/9/2018/06/PLANO_ESTADUAL_IRAS_2024_2027_FINAL.pdf.

8. Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(5):553-569. doi:10.1017/ice.2022.87. DOI: https://doi.org/10.1017/ice.2022.87

9. Centers for Disease Control and Prevention (CDC). Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection). In: NHSN Patient Safety Component Manual [online]. [citado 2026 fev 01]. Disponível em: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf.

10. Freire MP, Assis DB, Tavares BM, Brito VOC, Marinho I, Lapchik M, et al. Impact of COVID-19 on healthcare-associated infections: Antimicrobial consumption does not follow antimicrobial resistance. Clinics (Sao Paulo). 2023;78:100231. doi:10.1016/j.clinsp.2023.100231. DOI: https://doi.org/10.1016/j.clinsp.2023.100231

11. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241-251. doi:10.1016/S1473-3099(20)30477-1. DOI: https://doi.org/10.1016/S1473-3099(20)30477-1

12. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024 Aug 7:ciae403. doi:10.1093/cid/ciae403. DOI: https://doi.org/10.1093/cid/ciae403

13. Infectious Diseases Society of America. IDSA 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections [online]. 2024 [citado 2026 fev 01]. Disponível em: https://www.idsociety.org/practice-guideline/amr-guidance/.

14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9. DOI: https://doi.org/10.1097/01.CCM.0000217961.75225.E9

15. Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World Clin Infect Dis. 2019;69(8):1446-1455. doi:10.1093/cid/ciz173. DOI: https://doi.org/10.1093/cid/ciz173

16. Harada S, Aoki K, Ohkushi D, Okamoto K, Takehana K, Akatsuchi T, et al. Institutional outbreak involving multiple clades of IMP-producing Enterobacter cloacae complex sequence type 78 at a cancer center in Tokyo, Japan. BMC Infect Dis. 2021;21:289. doi:10.1186/s12879-021-05952-9. DOI: https://doi.org/10.1186/s12879-021-05952-9

17. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025. DOI: https://doi.org/10.1016/j.cmi.2021.11.025

18. Wei L, Feng Y, Lin J, Kang X, Zhuang H, Wen H, et al. Handwashing sinks as reservoirs of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: a prospective multicenter study. Front Public Health. 2024. doi:10.3389/fpubh.2024.1468521. DOI: https://doi.org/10.3389/fpubh.2024.1468521

19. Baleivanualala SC, et al. Environmental contamination with carbapenem-resistant Acinetobacter baumannii in healthcare settings in Fiji: a potential source of infection. Front Cell Infect Microbiol. 2024. doi:10.3389/fcimb.2024.1429443. DOI: https://doi.org/10.3389/fcimb.2024.1429443

20. Centers for Disease Control and Prevention (CDC). Considerations for reducing risk: water in healthcare facilities [online]. Atlanta: CDC; 2024 out 24 [citado 2026 fev 01]. Disponível em: https://www.cdc.gov/healthcare-associated-infections/php/toolkit/water-management.html.

21. Garcia RCL, et al. Comparison between polymyxin B and colistin outcomes in bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Int J Antimicrob Agents. 2023. doi:10.1016/j.ijantimicag.2023.106883. DOI: https://doi.org/10.1016/j.ijantimicag.2023.106883

22. Matuschek E, Åhman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin—evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter spp. Clin Microbiol Infect. 2018;24(8):865-870. doi:10.1016/j.cmi.2017.11.020. DOI: https://doi.org/10.1016/j.cmi.2017.11.020

23. Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163-171. doi:10.1093/cid/cix783. DOI: https://doi.org/10.1093/cid/cix783

24. Pearl A, Barlam TF, Calderwood MS. Contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. N Engl J Med. 2025 Dec 18;393(24):2475-2477. doi:10.1056/NEJMclde2502960. DOI: https://doi.org/10.1056/NEJMclde2502960

25. Popovich KJ, Aureden K, Ham DC, et al. SHEA/IDSA/APIC practice recommendation: strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(7):1039-1067. doi:10.1017/ice.2023.102. DOI: https://doi.org/10.1017/ice.2023.102

26. Alves Araújo L, dos Santos LS, Araújo da Silva FD, Oliveira JVS. Implicações do gerenciamento de antimicrobianos em um hospital público. Cad ESP [citado 2026 fev 01]. Disponível em: https://cadernos.esp.ce.gov.br/index.php/cadernos/article/download/1936/600/12605. DOI: https://doi.org/10.54620/cadesp.v18i1.1936

27. Sautter RL, Parrott JS, Nachamkin I, Diel C, Tom RJ, Bobenchik AM, et al. American Society for Microbiology evidence-based laboratory medicine practice guidelines to reduce blood culture contamination rates: a systematic review and meta-analysis. Clin Microbiol Rev. 2024 dez 10;37(4):e0008724. doi:10.1128/cmr.00087. DOI: https://doi.org/10.1128/cmr.00087-24

28. Agência Nacional de Vigilância Sanitária (BR). Boletins e relatórios das notificações de IRAS e outros eventos adversos: boletins e relatórios [online]. Brasília (DF): Agência Nacional de Vigilância Sanitária; 2022 [citado 2026 fev 01]. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/boletins-e-relatorios-das-notificacoes-de-iras-e-outros-eventos-adversos-1/boletins-e-relatorios-das-notificacoes-de-iras-e-outros-eventos-adversos.

Downloads

Published

2026-07-08

Issue

Vol. 20 No. 1 (2026): Cadernos ESP - Revista Cientí­fica da Escola de Saúde Pública do Ceará

Section

Original Article

Categories

License

Copyright (c) 2026 Cadernos ESP

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

1.
Alves Araújo L, Moreira Alves da Silva D, Faustino Souza L, Souza Oliveira JV. Microbial resistance associated with IPCSL in an adult ICU in Ceará. Cadernos ESP [Internet]. 2026 Jul. 8 [cited 2026 Jul. 8];20(1):e2661. Available from: https://cadernos.esp.ce.gov.br/index.php/cadernos/article/view/2661

Similar Articles

1-10 of 578

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)